Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX2853 Combinations in mCRPC
NCT04556617Phase 2Terminated
- Sponsor
- Opna Bio
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of PLX2853 in metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Opna Bio. Primary endpoints: Number of Participants With Dose-Limiting Toxicities, Incidence of Treatment-Emergent Adverse Events Related to Treatment and 1 more. Started Sep 2020; status: terminated.
02
Drugs
PLX2853
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04556617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556617.